Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549476 | 1.00 | KMT2A (0.51) | KMT2AHPGDMEN1PLA2G1BATG4B | |
| SCHEMBL6814349 | 0.86 | HPGD (0.61) | KMT2AHPGDMEN1ALDH1A1RAB9A | |
| SCHEMBL6813232 | 0.84 | SRC (0.48) | HPGDALDH1A1RAB9A | |
| SCHEMBL28409790 | 0.81 | KMT2A (0.55) | KMT2AHPGDMEN1PLA2G1BATG4B | |
| SCHEMBL14743543 | 0.79 | SRR (0.46) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL27963510 | 0.78 | PLA2G1B (0.58) | KMT2AHPGDMEN1PLA2G1BATG4B | |
| SCHEMBL27963512 | 0.78 | KMT2A (0.55) | KMT2AHPGDMEN1PLA2G1BATG4B | |
| SCHEMBL17087481 | 0.77 | MEN1 (0.55) | KMT2AHPGDMEN1PLA2G1BATG4B | |
| SCHEMBL338918 | 0.76 | MMP8 (0.54) | KMT2AHPGDMEN1PLA2G1BATG4B | |
| SCHEMBL3659473 | 0.76 | PLA2G1B (0.53) | KMT2AHPGDMEN1PLA2G1BATG4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130316953-A1 | NEW USES FOR AMINO ACID ANTICONVULSANTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2013-11-28 | — | — | US | claimed |
| EP-2210598-B1 | Anticonvulsant amino acids for the treatment of pain | RES CORP TECHNOLOGIES INC (US) | 2013-09-18 | — | — | EP | claimed |
| EP-1915140-B1 | NOVEL USE OF PEPTIDE COMPOUNDS FOR TREATING MUSCLE PAIN | UCB PHARMA GMBH (DE) | 2011-11-23 | — | — | EP | claimed |
| EP-1695703-B1 | Anticonvulsant amino acids for the treatment of obsessive-compulsive neurosis | RES CORP TECHNOLOGIES INC (US) | 2010-08-11 | — | — | EP | claimed |
| EP-2210598-A2 | Anticonvulsant amino acids for the treatment of pain | Research Corporation Technologies, Inc. (US) | 2010-07-28 | — | — | EP | claimed |
| EP-1373300-B1 | NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING NON NEUROPATHIC INFLAMMATORY PAIN | SANOL ARZNEI SCHWARZ GMBH (DE) | 2009-05-20 | — | — | EP | claimed |
| US-20080280835-A1 | Novel Use of Peptide Compounds For Treating Muscle Pain | UCB PHARMA GMBH (DE) | 2008-11-13 | — | — | US | claimed |
| EP-1915140-A2 | NOVEL USE OF PEPTIDE COMPOUNDS FOR TREATING MUSCLE PAIN | SCHWARZ PHARMA AG (DE) | 2008-04-30 | — | — | EP | claimed |
| EP-1486205-B1 | Use of anticonvulsant aminoacids for the treatment of migraine | RES CORP TECHNOLOGIES INC (US) | 2007-10-17 | — | — | EP | claimed |
| EP-1486206-B1 | Uses of anticonvulsant aminoacids for the treatment of bipolar disorders | RES CORP TECHNOLOGIES INC (US) | 2007-10-17 | — | — | EP | claimed |
| US-6803481-B2 | TREATING DIFFERENT TYPES AND SYMPTOMS OF ACUTE AND CHRONIC PAIN, ESPECIALLY NON NEUROPATHIC INFLAMMATORY PAIN IN MAMMALS. THE PAIN TO BE TREATED MAY BE E.G. CHRONIC INFLAMMATORY PAIN, RHEUMATOID ARTHRITIS PAIN AND/OR SECONDARY | SCHWARZ PHARMA AG (DE) | 2004-10-12 | — | — | US | claimed |
| US-20040097416-A1 | New uses for amino acid anticonvulsants | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2004-05-20 | — | — | US | claimed |
| US-20040087508-A1 | Users for amino acid anticonvulsants | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-05-06 | — | — | US | claimed |
| EP-1373300-A2 | NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING NON NEUROPATHIC INFLAMMATORY PAIN | SCHWARZ PHARMA AG (DE) | 2004-01-02 | — | — | EP | claimed |
| EP-1365787-A2 | NEW USES FOR AMINO ACID ANTICONVULSANTS FOR TREATMENT OF PAIN | Research Corporation Technologies, Inc (US) | 2003-12-03 | — | — | EP | claimed |
| US-20030171300-A1 | Treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary | UCB PHARMA GMBH (DE) | 2003-09-11 | — | — | US | claimed |
| WO-2002074784-A2 | NOVEL USE OF A PEPTIDE CLASS OF COMPOUND FOR TREATING NON NEUROPATHIC INFLAMMATORY PAIN | SCHWARZ PHARMA AG (DE) | 2002-09-26 | — | — | WO | claimed |
| EP-1243262-A1 | Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain | SCHWARZ PHARMA AG (DE) | 2002-09-25 | — | — | EP | claimed |
| US-20020086828-A1 | Uses for amino acid anticonvulsants | HARRIS ROBERT H (US) | 2002-07-04 | — | — | US | claimed |
| WO-2002015922-A2 | NEW USES FOR AMINO ACID ANTICONVULSANTS FOR TREATMENT OF PAIN | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2002-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086828-A1 | Uses for amino acid anticonvulsants | SLC1A2, SLC1A1, SLC1A3 | KMT2A 2585/4885HPGD 385/4885MEN1 560/4885 |
| US-20080280835-A1 | Novel Use of Peptide Compounds For Treating Muscle Pain | MTPN, MUSK, TNNC1 | KMT2A 4569/4885HPGD 1996/4885MEN1 4196/4885 |
| US-20040087508-A1 | Users for amino acid anticonvulsants | SLC1A2, SLC1A1, SLC1A3 | KMT2A 1884/4885HPGD 441/4885MEN1 654/4885 |
| US-20130316953-A1 | NEW USES FOR AMINO ACID ANTICONVULSANTS | SLC1A2, SLC1A1, SLC1A3 | KMT2A 2691/4885HPGD 539/4885MEN1 1053/4885 |
| US-20040097416-A1 | New uses for amino acid anticonvulsants | SLC1A2, SLC1A1, SLC1A3 | KMT2A 3090/4885HPGD 548/4885MEN1 757/4885 |
| US-20030171300-A1 | Treating different types and symptoms of acute and chronic pain, especially non neuropathic inflammatory pain in mammals. The pain to be treated may be e.g. chronic inflammatory pain, rheumatoid arthritis pain and/or secondary | OPRK1, OPRL1, PTGER1 | KMT2A 3253/4885HPGD 356/4885MEN1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.